|Download pdf||207.8 KB|
Company Announcement no. 27/2016
To: NASDAQ Copenhagen A/S Copenhagen, Denmark, 31 December 2016
Veloxis Announces the Total Number of Shares and Voting Rights in the Company as of 31 December 2016
Veloxis Pharmaceuticals A/S announces, in accordance with Section 10 of the Danish Statutory Order on Issuers' Disclosure Obligations, the total number of shares and voting rights in the company at the end of a calendar month in which changes to the share capital have occurred.
With reference to Company Announcement no. 25/2016 dated 19 December 2016 informing of an increase in the share capital and the voting rights after exercise of employee warrants, the table below provides the total number of shares and voting rights in Veloxis as of 31 December 2016.
Total number of shares
(nominal value of DKK 0.10 each)
(nominal value in DKK)
|Total number of votes|
|31 December 2016||1,703,373,881||170,337,388.10||1,703,373,881|
For more information, please contact:
Craig A. Collard
President & CEO
Phone: +1 919 591 3065
About Veloxis Pharmaceuticals
Veloxis Pharmaceuticals A/S is a commercial-stage specialty pharmaceutical company committed to improving the lives of transplant patients. A Danish company, Veloxis Pharmaceuticals A/S operates in the U.S. through Veloxis Pharmaceuticals Inc., a wholly-owned subsidiary headquartered in Cary, North Carolina, USA and maintains a second corporate office in Edison, New Jersey, USA. Veloxis has successfully developed Envarsus XR (tacrolimus extended-release tablets) based upon the company's unique and patented delivery technology, MeltDose®, which is designed to enhance the absorption and bioavailability of select orally administered drugs. The company is focused on the direct commercialization of Envarsus XR in the US, expansion of partnerships for markets around the world, and acquisition of assets utilized in transplant patients and by adjacent medical specialties. Veloxis is listed on the NASDAQ OMX Copenhagen under the trading symbol OMX: VELO. For further information, please visit www.veloxis.com.